•  
  •  
 

Journal of Emerging Technologies and Business Management

Abstract

BioTime is a biology based company focused in the medical related sector of the biotechnology industry. BioTime is predominantly in the race for a major breakthrough in stem cell research to provide a licensable, marketable and affordable product to improve lives by finding cures to both common and rare cancers and diseases. This case emphasizes the risky business position in which BioTime currently resides. With very high research and design costs and very little revenue, operations of the company heavily depend on investors and grants from both private and commercial sectors BioTime, which has been a "start-up company " since I990, has steadily increased the size and reach ofits company through strategic mergers, acquisitions and alliances with various companies, research institutes and colleges.

Share

COinS